Table of Contents

Chapter 1 Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Type segment
1.1.1.2. End-use segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective – 1
1.4.2. Objective – 2
1.4.3. Objective – 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2 Executive Summary
2.1. Market Snapshot
2.2. Type and End-use Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3 Urinary Tract Infection Market Variables, Trends, and Scope
3.1 Parent Market Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Industry Analysis – Porter’s
3.3.1 Threat Of New Entrants: Moderate
3.3.2 Bargaining Power Of Buyers: Moderate
3.3.3 Competitive Rivalry: High
3.3.4 Threat Of Substitutes: Low
3.3.5 Bargaining Power Of Suppliers: Moderate
3.4 PESTEL Analysis (Political & Legal, Economic, and Technological)
3.4.1 Political & Legal
3.4.2 Economic
3.4.3 Technological
3.5 Consumer Behavior Analysis
3.5.1 Complex Buying
3.5.2 Habitual Buying Behavior
3.5.3 Reducing Buying Behavior
3.5.4 Variety Seeking
3.6 Market Driver Analysis
3.6.1 Technological Advancements and Increasing Adoption of Home-Based Testing
3.6.2 Rising Target Disease Incidence, and Growing Geriatric Population
3.7 Market Restraint Analysis
3.7.1 Rapid Testing Sensitivity & Accuracy And Availability of Refurbished Urine Analyser
3.8 Urine Culture Tests Performed in the U.S. and Canada
Chapter 4 Urinary Tract Infection Market: Segment Analysis, by End Use, 2018 – 2030 (USD Million) (Volume, Units)
4.1 Urinary Tract Infection Market: End-use Movement Analysis
4.2 General Practitioners
4.2.1 General Practitioners Market, 2018 – 2030 (USD Million)
4.2.2 General Practitioners Market, Instruments, 2018 – 2030 (USD Million)
4.2.3 General Practitioners Market, Instruments, 2018 – 2030, Volume (Units)
4.2.4 General Practitioners Market, Consumables, 2018 – 2030 (USD Million)
4.2.5 General Practitioners Market, Consumables, 2018 – 2030, Volume (Thousand Units)
4.3 Urologists
4.3.1 Urologists Market, 2018 – 2030 (USD Million)
4.3.2 Urologists Market, Instruments, 2018 – 2030 (USD Million)
4.3.3 Urologists Market, Instruments, 2018 – 2030, Volume (Units)
4.3.4 Urologists Market, Consumables, 2018 – 2030 (USD Million)
4.3.5 Urologists Market, Consumables, 2018 – 2030, Volume (Thousand Units)
4.4 Urogynecologists
4.4.1 Urogynecologists Market, 2018 – 2030 (USD Million)
4.4.2 Urogynecologists Market, Instruments, 2018 – 2030 (USD Million)
4.4.3 Urogynecologists Market, Instruments, 2018 – 2030, Volume (Units)
4.4.4 Urogynecologists Market, Consumables, 2018 – 2030 (USD Million)
4.4.5 Urogynecologists Market, Consumables, 2018 – 2030, Volume (Thousand Units)
4.5 Reference Laboratories
4.5.1 Reference Laboratories Market, 2018 – 2030 (USD Million)
4.5.2 Reference Laboratories Market, Instruments, 2018 – 2030 (USD Million)
4.5.3 Reference Laboratories Market, Instruments, 2018 – 2030, Volume (Units)
4.5.4 Reference Laboratories Market, Consumables, 2018 – 2030 (USD Million)
4.5.5 Reference Laboratories Market, Consumables, 2018 – 2030, Volume (Thousand Units)
4.6 Accountable Care Organizations
4.7 Hospital Laboratories
4.7.1 Hospital Laboratories Market, 2018 – 2030 (USD Million)
4.7.2 Hospital Laboratories Market, Instruments, 2018 – 2030 (USD Million)
4.7.3 Hospital Laboratories Market, Instruments, 2018 – 2030, Volume (Units)
4.7.4 Hospital Laboratories Market, Consumables, 2018 – 2030 (USD Million)
4.7.5 Hospital Laboratories Market, Consumables, 2018 – 2030, Volume (Thousand Units)
4.8 Urgent Care
4.8.1 Urgent Care Market, 2018 – 2030 (USD Million)
4.8.2 Urgent Care Market, Instruments, 2018 – 2030 (USD Million)
4.8.3 Urgent Care Market, Instruments, 2018 – 2030, Volume (Units)
4.8.4 Urgent Care Market, Consumables, 2018 – 2030 (USD Million)
4.8.5 Urgent Care Market, Consumables, 2018 – 2030, Volume (Thousand Units)
4.9 Hospital Emergency Departments
4.9.1 Hospital Emergency Departments Market, 2018 – 2030 (USD Million)
4.9.2 Hospital Emergency Departments Market, Instruments, 2018 – 2030 (USD Million)
4.9.3 Hospital Emergency Departments Market, Instruments, 2018 – 2030, Volume (Units)
4.9.4 Hospital Emergency Departments Market, Consumables, 2018 – 2030 (USD Million)
4.9.5 Hospital Emergency Departments Market, Consumables, 2018 – 2030, Volume (Thousand Units)
4.10 Others
4.10.1 Others Market, 2018 – 2030 (USD Million)
4.10.2 Others Market, Instruments, 2018 – 2030 (USD Million)
4.10.3 Others Market, Instruments, 2018 – 2030, Volume (Units)
4.10.4 Others Market, Consumables, 2018 – 2030 (USD Million)
4.10.5 Others Market, Consumables, 2018 – 2030, Volume (Thousand Units)
Chapter 5 Urinary Tract Infection Market: Segment Analysis, by Type Scope, 2018 – 2030 (USD Million)
5.1 Urinary Tract Infection Market: Type Scope Movement Analysis
5.2 Urethritis
5.2.1 Urethritis Market, 2018 – 2030 (USD Million)
5.3 Cystitis
5.3.1 Cystitis market, 2018 – 2030 (USD Million)
5.4 Pyelonephritis
5.4.1 Pyelonephritis Market, 2018 – 2030 (USD Million)
Chapter 6 Urinary Tract Infection Market: Segment Analysis, By Region, 2018 – 2030 (USD Million)
6.1. Bloodstream Infection Testing Market Share By Region, 2022 & 2030
6.2. North America
6.2.1. North America Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.2.2. U.S.
6.2.3.1. Key Country Dynamics
6.2.2.2. Target Disease Prevalence
6.2.2.3. Competitive Scenario
6.2.2.4. Regulatory Framework
6.2.2.5. Reimbursement Scenario
6.2.2.6. U.S. Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Regulatory Framework
6.2.3.5. Reimbursement Scenario
6.2.3.6. Canada Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.3. Europe
6.3.1. Europe Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.3.2. UK
6.3.2.1. Key Country Dynamics
6.3.2.2. Target Disease Prevalence
6.3.2.3. Competitive Scenario
6.3.2.4. Regulatory Framework
6.3.2.5. Reimbursement Scenario
6.3.2.6. UK Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Regulatory Framework
6.3.3.5. Reimbursement Scenario
6.3.3.6. Germany Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. Regulatory Framework
6.3.4.5. Reimbursement Scenario
6.3.4.6. France Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.3.5. Italy
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Competitive Scenario
6.3.5.4. Regulatory Framework
6.3.5.5. Reimbursement Scenario
6.3.5.6. Italy Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.3.6. Spain
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Competitive Scenario
6.3.6.4. Regulatory Framework
6.3.6.5. Reimbursement Scenario
6.3.6.6. Spain Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Competitive Scenario
6.3.7.4. Regulatory Framework
6.3.7.5. Reimbursement Scenario
6.3.7.6. Denmark Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Competitive Scenario
6.3.8.4. Regulatory Framework
6.3.8.5. Reimbursement Scenario
6.3.8.6. Sweden Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.3.9. Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Competitive Scenario
6.3.9.4. Regulatory Framework
6.3.9.5. Reimbursement Scenario
6.3.9.6. Norway Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Competitive Scenario
6.4.2.4. Regulatory Framework
6.4.2.5. Reimbursement Scenario
6.4.2.6. Japan Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.4.3. China
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Regulatory Framework
6.4.3.5. Reimbursement Scenario
6.4.3.6. China Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. Regulatory Framework
6.4.4.5. Reimbursement Scenario
6.4.4.6. India Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.4.5. Australia
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Competitive Scenario
6.4.5.4. Regulatory Framework
6.4.5.5. Reimbursement Scenario
6.4.5.6. Australia Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.4.6. Thailand
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Competitive Scenario
6.4.6.4. Regulatory Framework
6.4.6.5. Reimbursement Scenario
6.4.6.6. Thailand Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.4.7. South Korea
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Competitive Scenario
6.4.7.4. Regulatory Framework
6.4.7.5. South Korea Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Competitive Scenario
6.5.2.4. Regulatory Framework
6.5.2.5. Reimbursement Scenario
6.5.2.6. Brazil Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.5.3. Mexico
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Competitive Scenario
6.5.3.4. Regulatory Framework
6.5.3.5. Reimbursement Scenario
6.5.3.6. Mexico Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.5.4. Argentina
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Competitive Scenario
6.5.4.4. Regulatory Framework
6.5.4.5. Reimbursement Scenario
6.5.4.6. Argentina Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.6. MEA
6.6.1. MEA Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Competitive Scenario
6.6.2.4. Regulatory Framework
6.6.2.5. Reimbursement Scenario
6.6.2.6. South Africa Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.6.3. Saudi Arabia
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Competitive Scenario
6.6.3.4. Regulatory Framework
6.6.3.5. Reimbursement Scenario
6.6.3.6. Saudi Arabia Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Competitive Scenario
6.6.4.4. Regulatory Framework
6.6.4.5. Reimbursement Scenario
6.6.4.6. UAE Bloodstream Infection Testing Market, 2018 – 2030 (USD Million)
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Competitive Scenario
6.6.5.4. Regulatory Framework
6.6.5.5. Reimbursement Scenario
6.6.5.6. Kuwait Bloodstream Infection Testing Market, 2018 – 2030 (USD Million
Chapter 7 Urinary Tract Infection Market: Competitive Analysis
7.1 Key Company Market Share Analysis, 2022
7.2 Company Profiles
7.2.1 QIAGEN
7.2.1.1 Company overview
7.2.1.2 Financial performance
7.2.1.3 Product benchmarking
7.2.1.4 Strategic initiatives
7.2.2 Accelerate Diagnostics, Inc.
7.2.2.1 Company overview
7.2.2.2 Financial performance
7.2.2.3 Product benchmarking
7.2.3 Bio-Rad Laboratories, Inc.
7.2.3.1 Company overview
7.2.3.2 Financial performance
7.2.3.3 Product benchmarking
7.2.4 F. Hoffmann-La Roche Ltd.
7.2.4.1 Company overview
7.2.4.2 Financial Performance
7.2.4.3 Product Benchmarking
7.2.4.4 Strategic initiatives
7.2.5 Danaher Corporation
7.2.5.1 Company overview
7.2.5.2 Beckman Coulter
7.2.5.3 Financial Performance
7.2.5.4 Product benchmarking
7.2.5.5 Strategic initiatives
7.2.6 Siemens Healthcare GmbH
7.2.6.1 Company overview
7.2.6.2 Financial performance
7.2.6.3 Product benchmarking
7.2.6.4 Strategic initiatives
7.2.7 Randox Laboratories Ltd.
7.2.7.1 Company overview
7.2.7.2 Product benchmarking
7.2.8 Thermo Fisher Scientific, Inc.
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Product benchmarking
7.2.8.4 Strategic initiatives
7.2.9 bioMérieux SA
7.2.9.1 Company overview
7.2.9.2 Financial performance
7.2.9.3 Product benchmarking
7.2.9.4 Strategic initiatives
7.2.10 T2 Biosystems, Inc.
7.2.10.1 Company overview
7.2.10.2 Financial performance
7.2.10.3 Product benchmarking
7.2.10.4 Strategic initiatives